Table 2.
Characteristics of IDRF-negative patients who underwent laparotomy or laparoscopic tumor resection
| Laparotomy (n = 9) | Laparoscopic surgery (n = 7) | p | |||
|---|---|---|---|---|---|
| Risk | Low/intermediate 3 (33%) | High 6 (67%) | Low/intermediate 2 (29%) | High 5 (71%) | 0.838 |
| Surgery | total removal 9 (100%) | total removal 7 (100%) | |||
| Age (month) a | 12 [9.5–48] | 28 [23–51] | 0.143 | ||
| Sex | male 6 (67%) | female 3 (33%) | male 3 (43%) | female 4 (57%) | 0.615 |
| Body weight (kg) a | 8.65 [8.09–15.2] | 11.8 [10.3–14.9] | 0.143 | ||
| Kaup index a | 15.32 [13.87–16.65] | 15.67 [15.51–16.45] | 0.626 | ||
| MYCN amplified | amplified 2 (22%), single copy 2 (22%), unknown 5 (56%) | amplified 2 (29%), single copy 2 (29%), unknown 3 (43%) | 0.771 | ||
| VMA (mg/gCr) a | 11.1 [9.6–17.0] | 9.1 [7.8–19.8] | 0.805 | ||
| HVA (mg/gCr) a | 21 [17.7–30.3] | 18.2 [11.2–30.4] | 0.805 | ||
| NSE (ng/mL) a | 9.6 [8.0–29.4] | 19.3 [12.4–21.0] | 0.326 | ||
| Largest tumor dimension at surgery (cm) a | 3.3 [2.9–4.1] | 3.6 [2.7–5.0] | 0.626 | ||
| Duration of surgery (min) a | 221 [130–304] | 172 [122–253] | 0.626 | ||
| Loss of blood volume (mL/kg) a | 5 [2.6–16] | 2.1 [0.1–4.0] | 0.037 b | ||
| Time to start postoperative feeding (days) a | 4 [2–5] | 3 [2–3] | 0.023 b | ||
| Locoregional recurrence (1 year) | 22% | 0% | 0.475 | ||
| Progression-free survival (1 year) | 78% | 100% | 0.414 | ||
| Overall survival (1 year) | 67% | 100% | 0.231 | ||
| Follow up (months) a | 81 [52–94] | 21 [17–28] | |||
IDRF image-defined risk factor, MYCN N-myc proto-oncogene protein, VMA vanillylmandelic acid, HVA homovanillic acid, NSE neuron-specific enolase
aMedian [Interquartile range] bSignificant differences